JP2022510218A5 - - Google Patents
Info
- Publication number
- JP2022510218A5 JP2022510218A5 JP2021530200A JP2021530200A JP2022510218A5 JP 2022510218 A5 JP2022510218 A5 JP 2022510218A5 JP 2021530200 A JP2021530200 A JP 2021530200A JP 2021530200 A JP2021530200 A JP 2021530200A JP 2022510218 A5 JP2022510218 A5 JP 2022510218A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- sequence numbers
- sequence
- immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024133895A JP2024174865A (ja) | 2018-11-30 | 2024-08-09 | ヘテロ二量体四価特異性抗体およびこれらの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862774111P | 2018-11-30 | 2018-11-30 | |
| US62/774,111 | 2018-11-30 | ||
| US201962794523P | 2019-01-18 | 2019-01-18 | |
| US62/794,523 | 2019-01-18 | ||
| PCT/US2019/063854 WO2020113164A1 (en) | 2018-11-30 | 2019-11-29 | Heterodimeric tetravalency and specificity antibody compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024133895A Division JP2024174865A (ja) | 2018-11-30 | 2024-08-09 | ヘテロ二量体四価特異性抗体およびこれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022510218A JP2022510218A (ja) | 2022-01-26 |
| JP2022510218A5 true JP2022510218A5 (enExample) | 2022-12-05 |
Family
ID=70853677
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530200A Pending JP2022510218A (ja) | 2018-11-30 | 2019-11-29 | ヘテロ二量体四価特異性抗体およびこれらの使用 |
| JP2024133895A Pending JP2024174865A (ja) | 2018-11-30 | 2024-08-09 | ヘテロ二量体四価特異性抗体およびこれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024133895A Pending JP2024174865A (ja) | 2018-11-30 | 2024-08-09 | ヘテロ二量体四価特異性抗体およびこれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220098329A1 (enExample) |
| EP (1) | EP3902834A4 (enExample) |
| JP (2) | JP2022510218A (enExample) |
| AU (1) | AU2019387482A1 (enExample) |
| CA (1) | CA3121168A1 (enExample) |
| WO (1) | WO2020113164A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| EP4185616A1 (en) | 2020-07-24 | 2023-05-31 | Cellectis S.A. | T-cells expressing immune cell engagers in allogenic settings |
| US12540188B2 (en) | 2020-08-05 | 2026-02-03 | Synthekine, Inc. | IL10Rα/IL2Rγ synthetic cytokines |
| EP4192489A4 (en) | 2020-08-05 | 2024-12-11 | Synthekine, Inc. | IL2RB-BINDING MOLECULES AND METHODS OF USE |
| KR102773428B1 (ko) | 2020-08-05 | 2025-02-28 | 신테카인, 인크. | Il10 수용체 결합 분자 및 사용 방법 |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| EP4210832A1 (en) * | 2020-09-14 | 2023-07-19 | Vor Biopharma, Inc. | Chimeric antigen receptors for treatment of cancer |
| WO2022108976A2 (en) * | 2020-11-18 | 2022-05-27 | Memorial Sloan Kettering Cancer Center | Anti-gpa33 multi-specific antibodies and uses thereof |
| WO2022150452A1 (en) * | 2021-01-06 | 2022-07-14 | Seth Lederman | Methods of inducing immune tolerance with modified anti-cd154 antibodies |
| WO2022150791A2 (en) * | 2021-01-11 | 2022-07-14 | Synthekine, Inc. | Compositions and methods related to il2 receptor binding |
| EP4288455A1 (en) | 2021-02-03 | 2023-12-13 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| AU2022277649A1 (en) | 2021-05-21 | 2023-11-30 | Cellectis S.A. | Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| WO2023055376A1 (en) * | 2021-09-30 | 2023-04-06 | Virtuoso Binco, Inc. | Multispecific antibodies for targeting cd47 and icam1 and methods of use thereof |
| AU2022373303A1 (en) * | 2021-10-20 | 2024-05-09 | Memorial Hospital For Cancer And Allied Diseases | Anti-tshr multi-specific antibodies and uses thereof |
| US20250251400A1 (en) | 2021-11-05 | 2025-08-07 | American Diagnostics & Therapy, Llc (Adxrx) | Monoclonal Antibodies Against Carcinoembryonic Antigens, and Their Uses |
| WO2023083381A1 (zh) | 2021-11-15 | 2023-05-19 | 成都百利多特生物药业有限责任公司 | 双特异性抗体-喜树碱类药物偶联物及其医药用途 |
| CN118804927A (zh) * | 2022-01-21 | 2024-10-18 | 和铂医药(上海)有限责任公司 | 抗b7-h7抗体或其抗原结合片段及制备方法和应用 |
| CN114685609B (zh) * | 2022-04-11 | 2023-04-14 | 东北农业大学 | 一种超短自组装抗菌肽fwr及其制备方法与应用 |
| US20250002588A1 (en) | 2023-04-07 | 2025-01-02 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
| CN118146376B (zh) * | 2024-05-09 | 2024-07-05 | 成都微芯新域生物技术有限公司 | Hla-g抗体及其制备方法和用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US7070995B2 (en) * | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US7125843B2 (en) * | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
| WO2009129538A2 (en) * | 2008-04-18 | 2009-10-22 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
| EP3323830B1 (en) * | 2010-06-19 | 2023-08-23 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
| ES2758994T3 (es) * | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| KR102060389B1 (ko) * | 2011-05-21 | 2019-12-31 | 마크로제닉스, 인크. | 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자 |
| PL2903691T3 (pl) * | 2012-10-05 | 2019-10-31 | Hoffmann La Roche | Sposoby diagnozowania i leczenia nieswoistego zapalenia jelit |
| HK1220465A1 (zh) * | 2013-03-06 | 2017-05-05 | Merrimack Pharmaceuticals, Inc. | 抗c-met串联fc双特异性抗体 |
| US10150800B2 (en) * | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
| CN105530959B (zh) * | 2013-03-15 | 2021-09-17 | 纪念斯隆-凯特琳癌症中心 | 多聚化技术 |
| WO2014177459A2 (en) * | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| BR112016018100A2 (pt) * | 2014-02-07 | 2018-02-20 | Univ Mcmaster | acoplador antigênico de células t trifuncional, métodos e usos do mesmo |
| WO2018140026A1 (en) * | 2017-01-27 | 2018-08-02 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
| JP6871155B2 (ja) * | 2014-07-25 | 2021-05-12 | メモリアル スローン ケタリング キャンサー センター | 二重特異性ｈｅｒ２及びｃｄ３結合分子 |
| CN114181309B (zh) * | 2015-05-21 | 2024-07-30 | 鳄鱼生物科学公司 | 新型多肽 |
| CN120795163A (zh) * | 2016-10-14 | 2025-10-17 | 丹娜法伯癌症研究所公司 | 模块化四聚体双特异性抗体平台 |
| EA201992546A1 (ru) * | 2017-04-24 | 2020-03-06 | Мемориал Слоан Кеттеринг Кэнсер Сентер | Средства на основе антител к cd33 |
-
2019
- 2019-11-29 JP JP2021530200A patent/JP2022510218A/ja active Pending
- 2019-11-29 EP EP19889678.9A patent/EP3902834A4/en active Pending
- 2019-11-29 CA CA3121168A patent/CA3121168A1/en active Pending
- 2019-11-29 AU AU2019387482A patent/AU2019387482A1/en active Pending
- 2019-11-29 WO PCT/US2019/063854 patent/WO2020113164A1/en not_active Ceased
- 2019-11-29 US US17/298,008 patent/US20220098329A1/en active Pending
-
2024
- 2024-08-09 JP JP2024133895A patent/JP2024174865A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022510218A5 (enExample) | ||
| Labrijn et al. | Bispecific antibodies: a mechanistic review of the pipeline | |
| Surowka et al. | Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins | |
| Sedykh et al. | Bispecific antibodies: design, therapy, perspectives | |
| US12448423B2 (en) | Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains | |
| TWI828625B (zh) | 引導及導航控制蛋白質以及彼之製造及使用方法 | |
| US20230340130A1 (en) | Multi-specific binding proteins for cancer treatment | |
| Xu et al. | Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody | |
| US20240010748A1 (en) | Bispecific antibody for claudin 18a2 and cd3 and application of bispecific antibody | |
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2023503943A (ja) | がんを治療するための組み合わせ療法 | |
| Urbanska et al. | Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells | |
| TWI908779B (zh) | 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法 | |
| CN117285642A (zh) | 制导和导航控制蛋白及其制备和使用方法 | |
| Golay et al. | Design and validation of a novel generic platform for the production of tetravalent IgG1-like bispecific antibodies | |
| WO2023056312A1 (en) | Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof | |
| WO2021185337A1 (zh) | 一种双特异性融合蛋白及其应用 | |
| US20230002488A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| Fine et al. | Mechanism-driven design of multispecific antibodies for targeted disease treatment | |
| EP4469478A1 (en) | Bispecific molecule with tunable affinity to a targetted antigen | |
| Li et al. | Highlights of 2019 protein engineering summit (PEGS) in Boston, USA: advancing antibody-based cancer therapies to the clinic | |
| Way et al. | Bioinspired design of artificial signaling systems | |
| JP2024513485A5 (enExample) | ||
| CN116874606B (zh) | 一种靶向trop2和cd3的双特异性抗体及其制备方法与应用 | |
| Wozniak-Knopp | Bispecific antibodies |